NCT00584961View on ClinicalTrials.gov

BIMET Study: Evolution of Metabolic and Cardiovascular Risks Factors in Patients With Bipolar Disorder

CompletedOBSERVATIONAL
Enrollment

553

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
Bipolar Disorder
Interventions
OTHER

non-interventional

non-interventional

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00584961 - BIMET Study: Evolution of Metabolic and Cardiovascular Risks Factors in Patients With Bipolar Disorder | Biotech Hunter | Biotech Hunter